As of 2024-12-15, the Relative Valuation of Summit Therapeutics Inc (SMMT) is (1.81) USD. This relative valuation is based on P/E multiples. With the latest stock price at 17.83 USD, the upside of Summit Therapeutics Inc based on Relative Valuation is -110.1%.
The range of the Relative Valuation is (2.09) - (2.18) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.6x - 17.3x | 17.0x |
| Forward P/E multiples | 5.1x - 18.5x | 11.8x |
| Fair Price | (2.09) - (2.18) | (1.81) |
| Upside | -111.7% - -112.2% | -110.1% |
| Date | P/E |
| 2024-12-12 | -141.97 |
| 2024-12-11 | -149.13 |
| 2024-12-10 | -142.77 |
| 2024-12-09 | -148.25 |
| 2024-12-06 | -147.30 |
| 2024-12-05 | -139.19 |
| 2024-12-04 | -139.83 |
| 2024-12-03 | -141.18 |
| 2024-12-02 | -146.90 |
| 2024-11-29 | -146.66 |
| 2024-11-27 | -150.48 |
| 2024-11-26 | -152.54 |
| 2024-11-25 | -152.46 |
| 2024-11-22 | -150.95 |
| 2024-11-21 | -146.34 |
| 2024-11-20 | -147.93 |
| 2024-11-19 | -158.90 |
| 2024-11-18 | -150.79 |
| 2024-11-15 | -145.47 |
| 2024-11-14 | -154.53 |
| 2024-11-13 | -154.69 |
| 2024-11-12 | -164.94 |
| 2024-11-11 | -172.96 |
| 2024-11-08 | -170.10 |
| 2024-11-07 | -167.64 |
| 2024-11-06 | -165.97 |
| 2024-11-05 | -162.00 |
| 2024-11-04 | -158.58 |
| 2024-11-01 | -150.87 |
| 2024-10-31 | -147.69 |
| 2024-10-30 | -148.17 |
| 2024-10-29 | -173.44 |
| 2024-10-28 | -176.69 |
| 2024-10-25 | -168.91 |
| 2024-10-24 | -154.61 |
| 2024-10-23 | -159.14 |
| 2024-10-22 | -163.58 |
| 2024-10-21 | -162.87 |
| 2024-10-18 | -168.51 |
| 2024-10-17 | -171.37 |
| 2024-10-16 | -186.39 |
| 2024-10-15 | -173.52 |
| 2024-10-14 | -160.88 |
| 2024-10-11 | -158.50 |
| 2024-10-10 | -147.85 |
| 2024-10-09 | -150.16 |
| 2024-10-08 | -156.43 |
| 2024-10-07 | -150.32 |
| 2024-10-04 | -151.67 |
| 2024-10-03 | -147.85 |